Lighthouse Investment Partners LLC purchased a new position in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 300,000 shares of the company's stock, valued at approximately $3,039,000. Lighthouse Investment Partners LLC owned about 1.34% of Oaktree Acquisition Corp. III Life Sciences at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. AQR Arbitrage LLC bought a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the fourth quarter worth $19,743,000. Shaolin Capital Management LLC bought a new stake in Oaktree Acquisition Corp. III Life Sciences during the 4th quarter worth about $5,478,000. Finally, K2 Principal Fund L.P. acquired a new stake in Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at about $1,945,000.
Oaktree Acquisition Corp. III Life Sciences Trading Down 0.1%
Shares of OACC stock traded down $0.01 during trading hours on Monday, reaching $10.45. 2,925 shares of the company were exchanged, compared to its average volume of 95,922. Oaktree Acquisition Corp. III Life Sciences has a fifty-two week low of $9.95 and a fifty-two week high of $10.85. The business has a fifty day moving average price of $10.23.
About Oaktree Acquisition Corp. III Life Sciences
(
Free Report)
Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.
Further Reading
Before you consider Oaktree Acquisition Corp. III Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oaktree Acquisition Corp. III Life Sciences wasn't on the list.
While Oaktree Acquisition Corp. III Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
